[go: up one dir, main page]

WO2025054426A1 - Films comestibles à image holographique transférable et procédés associés - Google Patents

Films comestibles à image holographique transférable et procédés associés Download PDF

Info

Publication number
WO2025054426A1
WO2025054426A1 PCT/US2024/045544 US2024045544W WO2025054426A1 WO 2025054426 A1 WO2025054426 A1 WO 2025054426A1 US 2024045544 W US2024045544 W US 2024045544W WO 2025054426 A1 WO2025054426 A1 WO 2025054426A1
Authority
WO
WIPO (PCT)
Prior art keywords
hours
edible
transferable
holographic image
food product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/045544
Other languages
English (en)
Inventor
Fiorenzo G. Omenetto
Giulia GUIDETTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of WO2025054426A1 publication Critical patent/WO2025054426A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L35/00—Foods or foodstuffs not provided for in groups A23L5/00 - A23L33/00; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/40—Colouring or decolouring of foods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A23P20/105—Coating with compositions containing vegetable or microbial fermentation gums, e.g. cellulose or derivatives; Coating with edible polymers, e.g. polyvinyalcohol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers

Definitions

  • the present disclosure provides a food product having an edible transferable holographic image film on at least one surface of the food product.
  • the edible transferable holographic image film includes silk fibroin in an amount by weight of at least 50%. at least 60%. at least 70%, at least 80%, at least 90%, or 100%.
  • the edible transferable holographic image film has a holographic image pattern on a first film surface and a non-pattemed substrate portion.
  • the edible transferable holographic image film has a total thickness of between 5 pm and 50 pm.
  • the holographic image pattern has an image pattern thickness of between 150 nm and 3 pm.
  • the holographic image pattern has lateral image feature dimensions of between 150 nm and 5 pm.
  • the non-pattemed substrate portion has a substrate thickness of between 4.85 pm and 49.85 pm.
  • the edible transferable holographic image film has a degree of beta-sheet crystallinity that is tuned to sustain the holographic image pattern through exposure for at least an exposure length of time to either: a temperature exceeding 40 °C and/or a relative humidity exceeding 95%.
  • the exposure length of time is between 2 hours and 24 hours.
  • the present disclosure provides a method of making a transferable holographic image film.
  • the method includes: cast molding a silk fibroin solution onto a holographic image mold; during or after the cast molding, tuning a degree of beta sheet crystallinity in the edible transferable holographic image film; removing the edible transferable holographic image film from the holographic image mold.
  • the tuning the degree of beta sheet crystallinity is tailored to sustain the holographic image pattern through exposure for at least an exposure length of time to either: a temperature exceeding 40 °C and/or a relative humidity exceeding 95%.
  • the exposure length of time is between 2 hours and 24 hours.
  • the silk fibroin solution has a silk fibroin concentration by weight of between 0.01% and 1%.
  • the holographic image mold has a depth dimension of between 150 nm and 3 pm and lateral dimensions of between 150 nm and 5 pm.
  • the cast molding thereby forms the edible transferable holographic image film within the mold.
  • Removing the edible transferable holographic image film from the holographic image mold and applying it to a food product produces an image fidelity of at least 90%, at least 95%, at least 98%, or at least 99%.
  • the edible holographic image film having the properties disclosed in the preceding paragraph and elsewhere herein.
  • the present disclosure provides an edible transferable holographic image film having the properties described in either of the two preceding paragraphs and disclosed elsewhere herein.
  • the present disclosure provides a method of using an edible transferable holographic image film.
  • the method includes applying a first instance of the edible holographic image film to a first surface of a food product.
  • Fig. 1 is a schematic representation of the fabrication process of holographic coatings on food using silk solution to obtain holographic transfer films.
  • silk fibroin refers to silk fibroin protein whether produced by silkworm, spider, or other insect, or otherwise generated (Lucas et al., Adv. Protein Chem, 13: 107-242 (1958)). Any type of silk fibroin can be used in different embodiments described herein.
  • Silk fibroin produced by silkworms such as Bombyx mori, is the most common and represents an earth-friendly, renewable resource.
  • silk fibroin used in a silk film may be attained by extracting sericin from the cocoons of B. mori.
  • Organic silkworm cocoons are also commercially available.
  • silks there are many different silks, however, including spider silk (e.g., obtained from Nephila clavipes), transgenic silks, genetically engineered silks, such as silks from bacteria, yeast, mammalian cells, transgenic animals, or transgenic plants, and variants thereof, that can be used. See, e.g., WO 97/08315 and U.S. Pat. No. 5,245,012, each of which is incorporated herein by reference in their entireties.
  • spider silk e.g., obtained from Nephila clavipes
  • transgenic silks e.g., obtained from Nephila clavipes
  • genetically engineered silks such as silks from bacteria, yeast, mammalian cells, transgenic animals, or transgenic plants, and variants thereof, that can be used. See, e.g., WO 97/08315 and U.S. Pat. No. 5,245,012, each of which is incorporated herein by reference in their entireties.
  • holographic refers to an image or a pattern generated by the interference of light with a patterned material.
  • a holographic image is an image formed from a grating having certain dimensions with respect to the wavelength of visible light, as described herein.
  • a grating pattern with proper dimensions relative to the wavelength of visible light is one example of a holographic pattern.
  • image fidelity is a statistical measure of the reproducibility of providing an image with a given modality.
  • image fidelity relates to a statistical measure of reproducibly providing a given image on a desired food surface following the transfer process.
  • a statistically significant number of transferable films can be produced and measured for individual performance in transferring the desired image to a food product, with the individual performances being tallied into a statistical measure of overall image fidelity 7 .
  • a fail rate is lowering that fail rate in transferring holographic images in an edible environment and image fidelity is one measurable way of reflecting that.
  • the present disclosure provides a food product having an edible transferable holographic image film on at least one surface of the food product.
  • features described elsewhere herein relating to the food product and/or the edible transferable holographic image film in other contexts are applicable here to the edible transferable holographic image film and vice versa.
  • the edible transferable holographic image film is composed of silk fibroin in an amount by weight of at least 50%. In some cases, the edible transferable holographic image film is composed of silk fibroin in an amount by weight of at least 60%. In some cases, the edible transferable holographic image film is composed of silk fibroin in an amount by weight of at least 70%. In some cases, the edible transferable holographic image film is composed of silk fibroin in an amount byweight of at least 80%. In some cases, the edible transferable holographic image film is composed of silk fibroin in an amount by weight of at least 90%. In some cases, the edible transferable holographic image film is composed of silk fibroin in an amount by weight of 100%.
  • the edible transferable holographic image film includes a holographic image pattern on a first surface and a non-pattemed substrate portion.
  • the holographic image pattern is the portion of the edible transferable holographic image film that is responsible for generating the holographic image.
  • the non-pattemed substrate portion is primarily present for structural support.
  • the edible transferable holographic image film has a total thickness of between 5 pm and 50 pm.
  • the total thickness can be at least 5 pm, at least 10 pm, at least 15 pm, or at least 20 pm.
  • the total thickness can be at most 50 pm, at most 40 pm, at most 30 pm, at most 25 pm, at most 20 pm, at most 15 pm, or at most 10 pm.
  • the edible transferable holographic image film may need to be particularly thin, so that it does not unduly impact the flavor or texture profile of the food product.
  • achieving the fine features required for a holographic image pattern within a thin film is a particularly challenging technical achievement.
  • the holographic image pattern has an image pattern thickness of between 150 nm and 3 pm.
  • the image pattern thickness can be at least 150 nm, at least 200 nm, at least 250 nm, at least 300 nm, at least 400 nm, at least 475 nm. at least 500 nm, at least 600 nm. at least 750 nm, or at least 1 pm.
  • the image pattern thickness can be at most 3 pm, at most 2.5 pm, at most 2 pm, or at most 1 pm. Without wishing to be bound by any particular theory, it is believed that achieving a high image fidelity with an image pattern thickness as disclosed is highly challenging.
  • the holographic image pattern has lateral image feature dimensions of between 150 nm and 5 pm.
  • the lateral image feature dimensions can be at least 150 nm, at least 200 nm, at least 250 nm, at least 300 nm, at least 400 nm, at least 475 nm, at least 500 nm, at least 600 nm, at least 750 nm, or at least 1 pm.
  • the lateral image feature dimensions can be at most 5 pm, at most 4 pm. at most 3 pm, at most 2.5 pm, at most 2 pm. or at most 1 pm. Without wishing to be bound by any particular theory, it is believed that achieving a high image fidelity with lateral image feature dimensions as disclosed is highly challenging.
  • the non-pattemed substrate portion has a substrate thickness of between 4.85 pm and 49.85 pm.
  • the substrate thickness can be at least 4.85 pm, at least 5 pm, at least 10 pm, at least 15 pm, or at least 20 pm.
  • the substrate thickness can be at most 49.85 pm, at most 40 pm, at most 30 pm, at most 25 pm, at most 20 pm, at most 15 pm, or at most 10 pm.
  • the values disclosed here account for the 150 nm minimal thickness of the holographic image pattern, but otherwise the values including the 0.85 decimal can be reasonably substituted by their nearest integer value (e.g., a thickness of between 5 pm and 50 pm).
  • the edible transferable holographic image film has a degree of beta-sheet crystallinity that is tuned to sustain, or enable the endurance of, the holographic image pattern through exposure for an exposure length of time to various conditions that are typically deleterious to food images.
  • the exposure can be to a temperature exceeding 40 °C.
  • the exposure can be to a relative humidity exceeding 95%.
  • the exposure length of time is between 2 hours and 24 hours. In some cases, the exposure length of time can be greater than 24 hours. In some cases, the exposure length of time is at least 3 hours. In some cases, the exposure length of time is at least 6 hours. In some cases, the exposure length of time is at least 9 hours. In some cases, the exposure length of time is at least 12 hours.
  • the exposure length of time is at least 15 hours. In some cases, the exposure length of time is at least 18 hours. In some cases, the exposure length of time is at most 20 hours. In some cases, the exposure length of time is at most 16 hours. In some cases, the exposure length of time is at most 12 hours. In some cases, the exposure length of time is at most 8 hours. In some cases, the exposure length of time is between 4 and 6 hours. In some cases, the exposure length of time is between 5 and 8 hours. In some cases, the exposure length of time is between 10 and 12 hours. In some cases, the exposure length of time is between 4 and 12 hours. In some cases, the exposure length of time is between 10 and 18 hours. In some cases, the exposure length of time is between 18 and 24 hours.
  • the beta-sheet crystallinity is tuned to sustain the holographic image pattern through exposure to a temperature exceeding 40 °C for between 2 hours and 24 hours. In some cases, the beta-sheet crystallinity is tuned to sustain the holographic image pattern through exposure to a temperature exceeding 40 °C for greater than 24 hours, at least 3 hours, at least 6 hours, at least 9 hours, at least 12 hours, at least 18 hours, or at most 20 hours, at most 16 hours, at most 12 hours, or at most 10 hours.
  • the beta-sheet crystallinity is tuned to sustain the holographic image pattern through exposure to a temperature exceeding 40 °C between 4 and 6 hours, between 5 and 8 hours, between 10 and 12 hours, between 4 and 12 hours, between 10 and 18 hours, or between 18 and 24 hours.
  • the beta-sheet crystallinity is tuned to sustain the holographic image pattern through exposure to a relative humidity exceeding 95% for between 2 hours and 24 hours. In some cases, the beta-sheet crystallinity' is tuned to sustain the holographic image pattern through exposure to a relative humidity exceeding 95% for greater than 24 hours, at least 3 hours, at least 6 hours, at least 9 hours, at least 12 hours, at least 18 hours, or at most 20 hours, at most 16 hours, at most 12 hours, or at most 10 hours.
  • the beta-sheet crystallinity is tuned to sustain the holographic image pattern through exposure to a relative humidity exceeding 95% between 4 and 6 hours, between 5 and 8 hours, between 10 and 12 hours, between 4 and 12 hours, between 10 and 18 hours, or between 18 and 24 hours.
  • the tuning of the beta-sheet crystallinity can be done by techniques known to those having ordinary skill in the art, including but not limited to, water vapor annealing.
  • the relative thickness of the image pattern thickness and the substrate thickness can impact performance.
  • the ratio between the image pattern thickness and the substrate thickness is between 1:5000 and 1:2. In some cases, the ratio is at least 1 :5000. at least 1:2500, at least 1: 1000, at least 1:500, at least 1 :250. at least 1: 100, at least 1:75, at least 1 :50, at least 1:25, at least 1: 10, at least 1:5, at least 1 :4, or at least 1:3.
  • the ratio can be at most 1 :2.
  • the edible transferable holographic image fdm is flavorless.
  • the edible transferable holographic image film can be used to provide a food product with unaltered flavor and a holographic image on a first surface.
  • the edible transferable holographic image film includes a flavorant.
  • the flavorant can optionally be introduced by inclusion in a silk fibroin solution used in making the edible transferable holographic image film.
  • the edible transferable holographic image film can be used to provide a food product with enhanced flavor and a holographic image on the first surface.
  • the edible transferable holographic image film includes a colorant.
  • the colorant can optionally be introduced by inclusion in a silk fibroin solution used in making the edible transferable holographic image film.
  • the colorant can be any food safe colorant.
  • the colorant is a pigment or a dye. The colorant can impact the appearance of the holographic image.
  • the edible transferable holographic image film includes one or more nutritional supplements, including but not limited to vitamins. In these cases, the edible transferable holographic image film can impact the nutritional content of the food product.
  • the food product can be a chip.
  • the food product can be a potato chip.
  • the edible transferable holographic image film can be transferred on the surface of any solid food or can be deposited on the liquid-air interface of any food that is originally liquid and solidifies over time.
  • the food can be raw, partially cooked, fully cooked, or frozen.
  • Examples of food products include, but are not limited to, fruits and vegetables, meat, seafood, fish, baking goods, and the like.
  • An example food product has an edible transferable holographic image film on at least one surface of the food product.
  • the edible transferable holographic image film can be tuned to endure certain conditions, such as certain temperature and humidity conditions, to which the food product is exposed. Tuning the edible transferable holographic image film may involve varying a degree of beta-sheet crystallinity.
  • the edible transferable holographic image film of the example food product may include silk fibroin in an amount by weight of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%.
  • the edible transferable holographic image film may have a total thickness of between 5 pm and 50 pm.
  • the edible transferable holographic image film may have a holographic image pattern on a first film surface and a non-pattemed substrate portion.
  • the holographic image pattern may have an image pattern thickness of between 150 nm and 3 pm.
  • the holographic image pattern may have lateral image feature dimensions of between 150 nm and 5 pm.
  • the non-pattemed substrate portion of the edible transferable holographic image film may have a substrate thickness of between 4.85 pm and 49.85 pm.
  • the edible transferable holographic image film of the example food product may have a degree of betasheet crystallinity that is tuned to sustain the holographic image pattern through exposure to a temperature exceeding 40 °C and/or a relative humidity exceeding 95% for at least an exposure length of time.
  • the exposure length of time may be between 2 hours and 24 hours.
  • the example food product may be at least one of a chip, a potato chip, a fruit, a vegetable, a meat, a seafood, a fish, a baked good, raw, cooked, partially cooked, or frozen.
  • the present disclosure provides an edible transferable holographic image film. Unless expressly indicated otherwise, features described elsewhere herein relating to the edible transferable holographic image film in other contexts (e.g., in the context of a food product or a method) are applicable here to the edible transferable holographic image film and vice versa.
  • the present disclosure provides a method of making an edible transferable holographic image film.
  • the method includes cast molding a silk fibroin solution onto a holographic image mold.
  • the method includes, during or after the cast molding, tuning a degree of beta-sheet crystallinity in the edible transferable holographic image film. The degree of beta-sheet crystallinity is tuned as described elsewhere herein to sustain, or enable the endurance of, the edible transferable holographic image film through various conditions as described elsewhere herein.
  • the method includes removing the edible transferable holographic image film from the holographic image mold.
  • Removing the edible transferable holographic image film from the holographic image mold and applying it to a food product produces an image fidelity of at least 90%.
  • the image fidelity is at least 95%.
  • the image fidelity is at least 98%.
  • the image fidelity is at least 99%.
  • An example method may include making an edible transferable holographic image film.
  • the example method may include cast molding a silk fibroin solution onto a holographic image mold, the silk fibroin solution having a silk fibroin concentration by weight of between 0.01% and 1%, the holographic image mold having a depth dimension of between 1 0 nm and 3 pm and lateral dimensions of between 150 nm and 5 pm, thereby forming the edible transferable holographic image film within the mold.
  • the edible transferable holographic image film may include a holographic image pattern on a first film surface and a non-pattemed substrate portion.
  • An amount of silk fibroin solution may be tailored to produce a total thickness of between 5 pm and 50 pm for the edible transferable holographic image film, an image pattern thickness of between 150 nm and 3 pm and lateral image feature dimensions of between 150 nm and 5 pm for the holographic image pattern, and a substrate thickness of between 4.85 pm and 49.85 pm for the non-pattemed substrate thickness.
  • the example method may further include, during or after the cast molding, tuning a degree of beta sheet crystallinity in the edible transferable holographic image film to sustain the holographic image pattern through exposure to a temperature exceeding 40 °C and/or a relative humidity exceeding 95% for at least an exposure length of time.
  • the holographic image pattern may endure exposure for a length of time that may be between 2 hours and 24 hours.
  • the example method may further include removing the edible transferable holographic image film from the holographic image mold, wherein removing the edible transferable holographic image film from the holographic image mold and applying it to a food product produces an image fidelity of at least 90%, at least 95%, at least 98%, or at least 99%.
  • An example edible transferable holographic image film may include a holographic image pattern on a first film surface and a non-pattemed substrate portion.
  • the edible transferable holographic image film may include silk fibroin in an amount by weight of at least 50%, at least 60%. at least 70%. at least 80%. at least 90%. or 100%.
  • the edible transferable holographic image film may have a total thickness of between 5 pm and 50 pm.
  • the holographic image pattern may have an image pattern thickness of between 150 nm and 3 pm.
  • the holographic image pattern may have lateral image feature dimensions of between 150 nm and 5 pm.
  • the non-pattemed substrate portion may have a substrate thickness of between 4.85 pm and 49.85 pm.
  • the edible transferable holographic image film may have a degree of beta-sheet crystal lini ty that is tuned to sustain the holographic image pattern through exposure to a temperature exceeding 40 °C and/or a relative humidity exceeding 95% for at least an exposure length of time.
  • the exposure length of time may be between 2 hours and 24 hours.
  • the holographic image mold has a depth dimension of between 150 nm and 3 pm and lateral dimensions of between 150 nm and 5 pm.
  • the present disclosure provides a method of using an edible transferable holographic image film.
  • the method includes applying a first instance of the edible transferable holographic image film to a first surface of a food product.
  • the method can include applying a second instance of the edible transferable holographic image film to a second surface of the food product.
  • wavy potato chips include various surfaces that are not flat relative to one another. Strips of the edible transferable holographic image film could be applied to different sides of the waves, thereby providing a holographic image across the entire wavey surface.
  • the hydration state of the food product surfaces can have a significant impact on edible transferable holographic image film performance.
  • the edible transferable holographic image film needs to be properly tailored to be insoluble prior to application.
  • the edible transferable holographic image film may need to have moisture added for adhesion (e.g., applying in a high humidity environment or prewetting the food surface).
  • the first surface is wet and the edible transferable holographic image film is annealed prior to applying the first instance to the first surface.
  • the second (third, fourth, nth, etc.) surface is wet and the edible transferable holographic image film is annealed prior to applying the second (third, fourth, nth, etc.) instance to the second (third, fourth, nth, etc.) surface.
  • the present disclosure provides a method of making an edible holographic image-providing powder. The method includes sub-dividing the edible transferable holographic image film disclosed elsewhere herein. The sub-dividing can be achieved by conventional means, such as ball milling.
  • the present disclosure provides an edible holographic image-providing powder.
  • the powder includes particles of the edible transferable holographic image film as described herein and correspondingly includes the various properties of the edible transferable holographic image film as described herein, unless the context clearly dictates otherwise.
  • the present disclosure provides an edible film having embedded therein the holographic image-providing powder.
  • the edible film can itself be made of silk fibroin or another edible material (e.g., gelatin).
  • edible films and powders described herein may be holographic or nonholographic. Some embodiments of the edible films and powders may provide optical qualities such as color, fluorescence, etc. Taking advantage of the holographic and/or non-holographic properties of the edible films and powders disclosed herein, in embodiments, the edible films may be used in a regulatory or security' application, such as to provide a physical representation of a food certification, an authenticity of origin or source, an anti-tampering or authenticity indication, or to provide some aspect of security for a consumable.
  • the edible film may provide a durable physical representation of a certificate of origin of a specialty or exotic fruit, a transparency or traceability indication of animal welfare standards used in meats for sale, an indication of GMO best practices used in a harvested consumable, an indication of authenticity of a non-lab grown food source, and the like.
  • the edible films and powders may provide an indication of versions or doses of consumables that bear certain possession restrictions, versus versions or doses of those consumables having a medical exemption or other unrestricted or exempted use.
  • the edible films may be used in a two-factor authentication application, such as by using an aspect of the film to gain access to a restricted website (e g., a forum to gain restricted access to additional inventory’ of a specialty consumable).
  • the edible films may be used to provide an optically -based physically unclonable function.
  • the edible films and poyvders may be used in a regulator ’ or security application such as to provide a dynamic indication of a food certification, an authenticity or certificate of origin or source, an anti-tampering or authenticity indication, or to provide some aspect of security for a consumable.
  • the edible films and powders may possess certain physical characteristics in place of or in addition to optical properties that may be dynamically triggered or leveraged for the disclosed applications.
  • the edible films may have multiple triggers to provide dynamic indications/representations.
  • the edible film may be designed to persist for a certain duration then degrade or undergo an alteration after a certain time or upon a trigger, such as exposure to air, water, smoke, light, microbes, temperature, humidity, biological fluids, or some other agent/reagent.
  • a trigger such as exposure to air, water, smoke, light, microbes, temperature, humidity, biological fluids, or some other agent/reagent.
  • an edible film may be applied to certain meats to provide an authentication that it is not lab-grown, imitation meat. The edible film may degrade upon reaching a threshold temperature or upon coming into contact with a liquid.
  • an edible film applied to a toothbrush bristle may undergo a color alteration upon initial use allowing users to know the toothbrush is in use, then may undergo timed degradation during extended use of the toothbrush.
  • films and powders that may be used to provide a dynamic security function.
  • the disclosed films may be applied to single-use items, such as hospital tubing or syringes, to provide assurance that the item has not already been used.
  • the films may alter or degrade upon first use. as previously described herein, thus providing a dynamic indication of use.
  • the disclosed films may be conformally applied to a surface.
  • the edible film may be formed into a roll of film to be distributed in pre-apportioned or custom sizes.
  • the disclosed films and powders may be transferred within a portion/layer of an item.
  • the films may be lenticularly printed to provide an image with an optical illusion.
  • the disclosed films and powders may also provide an aesthetic embellishment, or a branding function.
  • embodiments may include edible glitter.
  • the edible glitter may form part of the dynamic or durable security films described herein, or the edible glitter itself may also provide a security function such as by possessing the dynamic characteristics of degradation and/or alteration described herein.
  • the edible transferable image film has a degree of beta-sheet crystallinity that is tuned to sustain the image pattern through exposure to a temperature exceeding 40 °C and/or a relative humidity exceeding 95% for at least an exposure length of time, wherein the exposure length of time is between 2 hours and 24 hours.
  • the edible transferable image film is configured to degrade or undergo an alteration after at least one of a passage of time or a trigger, such as an exposure to at least one of air, water, smoke, light, microbes, temperature, humidity, biological fluids, an agent, or a reagent.
  • the product is supplied as a roll.
  • the regulatory feature is at least one of a food certification, an authenticity of origin or source, a transparency or traceability indication of animal welfare standards, a restricted use product, or an anti-tampering or authenticity indication.
  • the security feature is at least one of a two-factor authentication application or an optically -based physically unclonable function.
  • the edible transferable image film is configured to degrade or undergo an alteration after at least one of a passage of time or a trigger, wherein the trigger is an exposure to at least one of air, water, smoke, light, microbes, temperature, humidity, biological fluids, an agent, or a reagent.
  • Disclosed herein is a method of providing at least one of a regulatory feature or a security feature, described elsewhere herein, for a consumable product using an edible transferable holographic image film made by the method of any one of the preceding claims, the method comprising applying a first instance of the edible transferable holographic image film to a first surface of the consumable product.
  • the edible transferable holographic image film is configured to degrade or undergo an alteration after at least one of a passage of time or a trigger, such as those described elsewhere herein.
  • a food product such as those described herein, having an edible transferable image film on at least one surface of the food product, the edible transferable image film comprising silk fibroin in an amount by weight of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%, the edible transferable image film having an image pattern on a first film surface and a non-pattemed substrate portion, wherein the edible transferable image film has a total thickness of between 5 pm and 50 pm. wherein the image pattern has an image pattern thickness of between 150 nm and 3 pm, wherein the image pattern has lateral image feature dimensions of between 150 nm and 5 pm.
  • the non-pattemed substrate portion has a substrate thickness of between 4.85 pm and 49.85 pm
  • the edible transferable image film has a degree of beta-sheet crystallinity that is tuned to sustain the image pattern through exposure to a temperature exceeding 40 °C and/or a relative humidity exceeding 95% for at least an exposure length of time, wherein the exposure length of time is between 2 hours and 24 hours.
  • the food product may be raw, cooked/partially cooked, or frozen.
  • the exposure length of time is between 4 and 6 hours, between 5 and 8 hours, between 10 and 12 hours, between 4 and 12 hours, between 10 and 18 hours, or between 18 and 24 hours, or at least 3 hours, at least 6 hours, at least 9 hours, at least 12 hours, at least 18 hours, or at most 20 hours, at most 16 hours, at most 12 hours, or at most 10 hours.
  • a method of making an edible transferable image film including cast molding a silk fibroin solution onto an image mold, the silk fibroin solution having a silk fibroin concentration by weight of between 0.01% and 1%, the image mold having a depth dimension of between 150 nm and 3 pm and lateral dimensions of between 150 nm and 5 pm, thereby forming the edible transferable image film within the mold, the edible transferable image film comprising an image pattern on a first film surface and a non-pattemed substrate portion, wherein an amount of silk fibroin solution is tailored to produce a total thickness of between 5 pm and 50 pm for the edible transferable image film, an image pattern thickness of between 150 nm and 3 pm and lateral image feature dimensions of between 150 nm and 5 pm for the image pattern, and a substrate thickness of between 4.85 pm and 49.85 pm for the non-pattemed substrate thickness.
  • the method includes tuning a degree of beta sheet crystallinity in the edible transferable image film to sustain the image pattern through exposure to a temperature exceeding 40 °C and/or a relative humidity exceeding 95% for at least an exposure length of time, wherein the exposure length of time is between 2 hours and 24 hours, and removing the edible transferable image film from the image mold.
  • Removing the edible transferable image film from the image mold and applying it to a food product produces an image fidelity of at least 90%, at least 95%, at least 98%, or at least 99%.
  • a method of using the edible transferable image film may include applying a first instance of the edible transferable image film to a first surface of a food product.
  • a product having an edible transferable holographic image film on at least one surface of the product comprising silk fibroin in an amount by weight of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%, the edible transferable holographic image film having a holographic image pattern on a first film surface and a non-pattemed substrate portion, wherein the edible transferable holographic image film has a total thickness of between 5 pm and 50 pm, wherein the holographic image pattern has an image pattern thickness of between 150 nm and 3 pm, wherein the holographic image pattern has lateral image feature dimensions of between 150 nm and 5 pm, wherein the non-pattemed substrate portion has a substrate thickness of between 4.85 pm and 49.85 pm, where
  • the edible transferable holographic image film is configured to degrade or undergo an alteration after at least one of a passage of time or a trigger (e.g., an exposure to at least one of air, water, smoke, light, microbes, temperature, humidity, biological fluids, an agent, or a reagent).
  • a trigger e.g., an exposure to at least one of air, water, smoke, light, microbes, temperature, humidity, biological fluids, an agent, or a reagent.
  • the product is at least one of a medicament, a nutraceutical, a supplement, or a cannabis edible, and may be supplied as a roll.
  • the exposure length of time is between 4 and 6 hours, between 5 and 8 hours, between 10 and 12 hours, between 4 and 12 hours, between 10 and 18 hours, or between 18 and 24 hours, or at least 3 hours, at least 6 hours, at least 9 hours, at least 12 hours, at least 18 hours, or at most 20 hours, at most 16 hours, at most 12 hours, or at most 10 hours.
  • Disclosed herein is a method of providing at least one of a regulatory feature or a security feature, as elsewhere described herein, for a consumable product using an edible transferable holographic image film including applying a first instance of the edible transferable holographic image film to a first surface of the consumable product.
  • the edible transferable holographic image film is configured to degrade or undergo an alteration after at least one of a passage of time or a trigger, as elsewhere described herein.
  • a variety of functionalizing agents may be used with the silk-containing embodiments described herein (e.g., silk membrane, silk composition, silk articles, silk matrix, silk foam, silk microsphere, liquid composition, whipped silk cream, silk meringue, compressed silk meringue, hot-pressed silk meringue, silk leather, silk powder, silk toner, edible silkbased films, etc.). It should be understood that the examples herein may recite one or a few silkcontaining embodiments but are applicable to any silk-containing embodiment, as applicable.
  • a functionalizing agent may be any compound or molecule that facilitates the attachment to and/or development (e.g., growth) of one or more endothelial cells on a silk membrane.
  • a functionalizing agent may be any compound or molecule that facilitates the attachment and/or development (e.g., growth) of one or more megakaryocytes and/or hematopoietic progenitor cells on a silk matrix and/or silk membrane.
  • a functionalizing agent may be or comprise an agent suitable for facilitating the production of one or more of white blood cells and red blood cells.
  • a functionalizing agent may be or comprise a cell attachment mediator and/or an extracellular matrix protein, for example: collagen (e.g., collagen type I, collagen type III, collagen type IV or collagen type VI), elastin, fibronectin, vitronectin, laminin, fibrinogen, von Willebrand factor, proteoglycans, decorin, perlecan, nidogen, hyaluronan, and/or peptides containing known integrin binding domains e.g. “RGD” integrin binding sequence, or variations thereof, that are known to affect cellular attachment.
  • collagen e.g., collagen type I, collagen type III, collagen type IV or collagen type VI
  • elastin e.g., fibronectin, vitronectin, laminin, fibrinogen, von Willebrand factor, proteoglycans, decorin, perlecan, nidogen, hyaluronan
  • peptides containing known integrin binding domains e
  • a functionalizing agent may be any soluble molecule produced by endothelial cells.
  • Non-limiting examples include fibroblast growth factor-1 (FGF1) and vascular endothelial growth factors (VEGF).
  • compositions may comprise the use of laminin, fibronectin and/or fibrinogen, and type IV collagen in order to facilitate the attachment and growth of endothelial cells on a silk membrane (e.g., a porous silk membrane) and/or attachment of megakary ocytes to a silk matrix.
  • a silk membrane e.g., a porous silk membrane
  • a functionalizing agent may be embedded or otherwise associated with a silk membrane and/or silk matrix such that at least a portion of the functionalizing agent is surrounded by a silk membrane and/or silk matrix as contrasted to a functionalizing agent simply being positioned along the surface of a silk membrane and/or silk matrix.
  • a functionalizing agent is distributed along and/or incorporated in substantially the entire surface area of a silk membrane/silk wall.
  • a functionalizing agent is distributed and/or incorporated only at one or more discrete portions of a silk membrane/wall and/or silk matrix.
  • a functionalizing agent is distributed in and/or along at least one of the lumenfacing side of a silk wall and the matrix-facing side of a silk wall.
  • any application-appropriate amount of one or more functionalizing agents may be used.
  • the amount of an individual functionalizing agent may be between about 1 pg/ml and 1,000 pg/ml (e.g., between about 2 and 1,000, 5 and 1,000, 10 and 1,000, 10 and 500, 10 and 100 pg/ml).
  • the amount of an individual functionalizing agent may be at least 1 pg/ml (e.g.. at least 5, 10, 15, 20 25, 50, 100, 200, 300 400, 500. 600, 700. 800, or 900 pg/ml ).
  • the amount of an individual functionalizing agent is at most 1,000 pg/ml (e.g., 900, 800, 700, 600, 500, 400, 300 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, or 5 pg/ml ).
  • the composition comprises one or more sensing agents, such as a sensing dye.
  • the sensing agents/sensing dyes are environmentally sensitive and produce a measurable response to one or more environmental factors.
  • the environmentally- sensitive agent or dye may be present in the composition in an effective amount to alter the composition from a first chemical -physical state to a second chemical -physical state in response to an environmental parameter (e.g., a change in pH, light intensify or exposure, temperature, pressure or strain, voltage, physiological parameter of a subject, and/or concentration of chemical species in the surrounding environment) or an externally applied stimulus (e.g., optical interrogation, acoustic interrogation, and/or applied heat).
  • an environmental parameter e.g., a change in pH, light intensify or exposure, temperature, pressure or strain, voltage, physiological parameter of a subject, and/or concentration of chemical species in the surrounding environment
  • an externally applied stimulus e.g., optical interrogation, acoustic interrogation, and/or applied heat
  • the sensing dye is present to provide one optical appearance under one given set of environmental conditions and a second, different optical appearance under a different given set of environmental conditions.
  • Suitable concentrations for the sensing agents described herein can be the concentrations for the colorants and additives described elsewhere herein. A person having ordinary' skill in the chemical sensing arts can determine a concentration that is appropriate for use in a sensing application of the inks described herein.
  • the first and second chemical-physical state may be a physical property of the composition, such as mechanical property 7 , a chemical property, an acoustical property, an electrical property, a magnetic property, an optical property, a thermal property, a radiological property, or an organoleptic property.
  • exemplary sensing dyes or agents include, but are not limited to, a pH sensitive agent, a thermal sensitive agent, a pressure or strain sensitive agent, a light sensitive agent, or a potentiometric agent.
  • Exemplary' pH sensitive dyes or agents include, but are not limited to, cresol red, methyl violet, crystal violet, ethyl violet, malachite green, methyl green, 2-(p- dimethylaminophenylazo) pyridine, paramethyl red, metanil yellow, 4-phenylazodiphenylamine, thymol blue, metacresol purple, orange IV, 4-o-Tolylazo-o-toluindine, quinaldine red, 2,4- dinitrophenol, erythrosine disodium salt, benzopurpurine 4B, N,N-dimethyl-p-(m-tolylazo) aniline, p- dimethylaminoazobenene, 4,4'-bis(2-amino-l-naphthylazo)-2,2'-stilbenedisulfonic acid, tetrabromophenolphthalein ethyl ester, bromophenol blue, Congo red, methyl orange, ethyl orange,
  • alizarin 2-(2.4- dinitrophenylazo) l-napthol-3.6-disulfonic acid bromothymol blue.
  • Exemplary light responsive dyes or agents include, but are not limited to, photochromic compounds or agents, such as triarylmethanes, stilbenes, azasilbenes, nitrones, fulgides, spiropyrans, napthopyrans, spiro-oxzines, quinones, derivatives and combinations thereof.
  • photochromic compounds or agents such as triarylmethanes, stilbenes, azasilbenes, nitrones, fulgides, spiropyrans, napthopyrans, spiro-oxzines, quinones, derivatives and combinations thereof.
  • Exemplary potentiometric dyes include, but are not limited to, substituted amiononaphthylehenylpridinium (ANEP) dyes, such as di-4-ANEPPS. di-8-ANEPPS. and N-(4- Sulfobutyl)-4-(6-(4-(Dibutylamino)phenyl)hexatrienyl)Pyridinium (RH237).
  • ANEP substituted amiononaphthylehenylpridinium
  • RH237 N-(4- Sulfobutyl)-4-(6-(4-(Dibutylamino)phenyl)hexatrienyl)Pyridinium
  • Exemplary 7 temperature sensitive dyes or agents include, but are not limited to, thermochromic compounds or agents, such as thermochromic liquid cry stals, leuco dyes, fluoran dyes, octadecylphosphonic acid.
  • Exemplary pressure or strain sensitive dyes or agents include, but are not limited to, spiropyran compounds and agents.
  • chemi-sensitive dyes or agents include, but are not limited to, antibodies such as immunoglobulin G (IgG) yvhich may change color from blue to red in response to bacterial contamination.
  • IgG immunoglobulin G
  • the compositions comprise one or more additive, dopant, or biologically active agent suitable for a desired intended purpose.
  • the additive or dopant may be present in the composition in an amount effective to impart an optical or organoleptic property to the composition.
  • Exemplary additives or dopants that impart optical or organoleptic properties include, but are not limited to, dyes/pigments, flavorants, aroma compounds, granular or fibrous fillers.
  • the additive, dopant, or biologically active agent may be present in the composition in an amount effective to "functionalize” the composition to impart a desired mechanical property or added functionality to the composition.
  • exemplary additive, dopants, or biologically active agent that impart the desired mechanical property or added functionality include, but are not limited to: environmentally sensitive/sensing dyes; active biomolecules; conductive or metallic particles; micro and nanofibers (e.g., silk nanofibers for reinforcement, carbon nanofibers); nanotubes; inorganic particles (e.g., hydroxyapatite, tricalcium phosphate, bioglasses); drugs (e.g.. antibiotics, small molecules or low molecular weight organic compounds); proteins and fragments or complexes thereof (e.g., enzymes, antigens, antibodies and antigen-binding fragments thereol);
  • DNA/RNA e.g., siRNA, miRNA, mRNA
  • cells and fractions thereof viruseses and viral particles; prokaryotic cells such as bacteria; eukaryotic cells such as mammalian cells and plant cells; fungi).
  • exemplary flavorants include ester flavorants, amino acid flavorants, nucleic acid flavorants, organic acid flavorants, and inorganic acid flavorants, such as, but not limited to.
  • the additive or dopant comprises an aroma compound.
  • aroma compounds include ester aroma compounds, terpene aroma compounds, cyclic terpenes, and aromatic aroma compounds, such as, but not limited to, geranyl acetate, methyl formate, metyl acetate, methyl propionate, methyl butyrate, ethyl acetate, ethyl butyrate, isoamyl acetate, pentyl butrate, pentyl pentanoate, octyl acetate, benzyl acetate, methyl anthranilate, myrecene, geraniol, nerol, citral, cironellal, cironellol, linalool, nerolidol, limonene, camphor, menthol, carone, terpineol, alpha-lonone, thujone, eucalyptol, benzaldehy
  • the additive or dopant comprises a colorant, such as a dye or pigment.
  • the dye or pigment imparts a color or grayscale to the composition.
  • the colorant can be different than the sensing agents and/or sensing dyes below. Any organic and/or inorganic pigments and dyes can be included in the inks.
  • Exemplary pigments suitable for use in the present disclosure include International Color Index or C.I. Pigment Black Numbers 1 , 7, 1 1 and 31 . C.I. Pigment Blue Numbers 15, 15 : 1 , 15 :2, 15 :3, 15 :4, 15 :6, 16, 27, 29, 61 and 62, C.I. Pigment Green Numbers 7, 17, 18 and 36, C.I.
  • carbon black pigment such as Regal 330, Cabot Corporation
  • quinacridone pigments Quinacridone Magenta (228-0122), available from Sun Chemical Corporation, Fort Lee, N.J.
  • diarylide yellow pigment such as AAOT Yellow (274- 1788) available from Sun
  • the classes of dyes suitable for use in present invention can be selected from acid dyes, natural dyes, direct dyes (either cationic or anionic), basic dyes, and reactive dyes.
  • the acid dyes also regarded as anionic dyes, are soluble in water and mainly insoluble in organic solvents and are selected, from yellow acid dyes, orange acid dyes, red acid dyes, violet acid dyes, blue acid dyes. green acid dyes, and black acid dyes.
  • European Patent 0745651 incorporated herein by reference, describes a number of acid dyes that are suitable for use in the present disclosure.
  • Exemplary’ yellow acid dyes include Acid Yellow 1 International Color Index or C.I. 10316); Acid Yellow 7 (C.I. 56295); Acid Yellow 17 (C.I.
  • Exemplary orange acid dyes include Acid Orange 1 (C.I. 13090/1); Acid Orange 10 (C.I. 16230); Acid Orange 20 (C.I. 14603); Acid Orange 76 (C.I. 18870); Acid Orange 142; Food Orange 2 (C.I. 15980); and Orange B. [0085] Exemplary red acid dyes include Acid Red 1. (C.I. 19140); Acid Yellow 29 (C.I. 18900); Acid Yellow 36 (C.I. 13065); Acid Yellow 42 (C.I. 22910); Acid Yellow 73 (C.I. 45350); Acid Yellow 99 (C.I. 13908); Acid Yellow 194; and Food Yellow 3 (C.I. 15985).
  • Exemplary orange acid dyes include Acid Orange 1 (C.I. 13090/1); Acid Orange 10 (C.I. 16230); Acid Orange 20 (C.I. 14603); Acid Orange 76 (C.I. 18870); Acid Orange 142; Food Orange 2 (C.I. 15980); and Orange B. [00
  • Acid Red 4 C.I. 14710
  • Acid Red 18 C.I. 16255
  • Acid Red 26 C.I. 16150
  • Acid Red 2.7 C.I. as Acid Red 51 (C.I. 45430, available from BASF Corporation, Mt. Olive. N.J.)
  • Acid Red 52 C.I. 45100
  • Acid Red 73 C.I. 27290
  • Acid Red 87 C. I. 45380
  • Acid Red 94 C.I. 45440
  • Acid Red 194 C.I. 14700
  • Exemplary' violet acid dyes include Acid Violet 7 (C.I. 18055); and Acid Violet 49 (C.I. 42640).
  • Exemplary' blue acid dyes include Acid Blue 1 (C.I.
  • Exemplary green acid dyes include Acid Green 1 (C.I. 10028); Acid Green 3 (C.I. 42085); Acid Green 5 (C.I. 42095); Acid Green 26 (C.I. 44025); and Food Green 3 (C.I. 42053).
  • Exemplary' black acid dyes include Acid Black 1 (C.I. 20470); Acid Black 194 (Basantol® X80, available from BASF Corporation, an azo/1 :2 CR-complex.
  • Exemplary direct dyes for use in the present disclosure include Direct Blue 86 (C.I. 74180); Direct Blue 199; Direct Black 168; Direct Red 253; and Direct Yellow 107/132 (C.I. Not Assigned).
  • Exemplary natural dyes for use in the present disclosure include Alkanet (C.I. 75520,75530); Annafto (C.I. 75120); Carotene (C.I. 75130); Chestnut; Cochineal (C.I.75470): Cutch (C.I. 75250, 75260); Divi-Divi; Fustic (C.I. 75240); Hypemic (C.I. 75280); Logwood (C.I. 75200); Osage Orange (C.I.
  • Exemplary 7 reactive dyes for use in the present disclosure include Reactive Yellow 37 (monoazo dye); Reactive Black 31 (disazo dye);
  • Reactive Blue 77 phthalo cyanine dye
  • Reactive Red 180 and Reactive Red 108 dyes Suitable also are the colorants described in The Printing Ink Manual (5th ed., Leach et al. eds. (2007), pages 289-299.
  • Other organic and inorganic pigments and dyes and combinations thereof can be used to achieve the colors desired.
  • compositions provided herein can contain ETV fluorophores that are excited in the ETV range and emit light at a higher wavelength (typically 400 nm and above).
  • ETV fluorophores include but are not limited to materials from the coumarin, benzoxazole, rhodamine, napthalimide. perylene, benzanthrones, benzoxanthones or benzothia- xanthones families.
  • a UV fluorophore such as an optical brightener for instance
  • the amount of colorant, when present, generally is between 0.05% to 5% or between 0.1% and 1% based on the weight of the composition.
  • the amount of pigment/dye generally is present in an amount of from at or about 0. 1 wt% to at or about 20 wt% based on the weight of the composition.
  • anon-white ink can include 15 wt% or less pigment/dye, or 10 wt% or less pigment/dye or 5 wt% pigment/dye, or 1 wt% pigment/dye based on the weight of the composition.
  • a non-white ink can include 1 wt% to 10 wt%, or 5 wt% to 15 wt%, or 10 wt% to 20 wt% pigment/dye based on the weight of the composition.
  • a non-white ink can contain an amount of dye/pigment that is 1 wt%, 2 wt%, 3 wt%, 4 wt%, 5%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, 10 wt%, 11 wt%, 12 wt%, 13 wt%, 14 wt%, 15%, 16 wt%, 17 wt%, 18 wt%, 19 wt% or 20 wt% based on the weight of the composition.
  • the amount of white pigment generally is present in an amount of from at or about 1 wt% to at or about 60 wt% based on the weight of the composition. In some applications, greater than 60 wt% white pigment can be present.
  • Preferred white pigments include titanium dioxide (anatase and rutile), zinc oxide, lithopone (calcined coprecipitate of barium sulfate and zinc sulfide), zinc sulfide, blanc fixe and alumina hydrate and combinations thereof, although any of these can be combined with calcium carbonate.
  • a white ink can include 60 wt% or less white pigment, or 55 wt% or less white pigment, or 50 wt% white pigment, or 45 wt% white pigment, or 40 wt% white pigment, or 35 wt% white pigment, or 30 wt% white pigment, or 25 wt% white pigment, or 20 wt% white pigment, or 15 wt% white pigment, or 10 wt% white pigment, based on the weight of the composition.
  • a white ink can include 5 wt% to 60 wt%, or 5 wt% to 55 wt%, or 10 wt% to 50 wt%, or 10 wt% to 25 wt%, or 25 wt% to 50 wt%, or 5 wt% to 15 wt%, or 40 wt% to 60 wt% white pigment based on the weight of the composition.
  • a non-white ink can an amount of dye/pigment that is 5%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, 10 wt%, 11 wt%, 12 wt%, 13 wt%, 14 wt%, 15%.
  • the additive or dopant comprises a conductive additive.
  • exemplary' conductive additives include, but are not limited to graphite, graphite powder, carbon nanotubes, and metallic particles or nanoparticles, such as gold nanoparticles.
  • the conductive additive is biocompatible and non-toxic.
  • the additive is a biologically active agent.
  • biologically active agent refers to any molecule which exerts at least one biological effect in vivo.
  • the biologically active agent can be a therapeutic agent to treat or prevent a disease state or condition in a subject.
  • Biologically active agents include, without limitation, organic molecules, inorganic materials, proteins, peptides, nucleic acids (e.g., genes, gene fragments, gene regulatory' sequences, and antisense molecules), nucleoproteins, polysaccharides, glycoproteins, and lipoproteins.
  • Classes of biologically active compounds that can be incorporated into the composition provided herein include, without limitation, anticancer agents, antibiotics, analgesics, antiinflammatory agents, immunosuppressants, enzyme inhibitors, antihistamines, anti-convulsants, hormones, muscle relaxants, antispasmodics, ophthalmic agents, prostaglandins, anti-depressants, anti-psychotic substances, trophic factors, osteoinductive proteins, growth factors, and vaccines.
  • active agent may also be used herein to refer to a biological sample (e.g., a sample of tissue or fluid, such as for instance blood) or a component thereof, and/or to a biologically active entity' or compound, and/or to a structurally or functionally labile entity'.
  • Exemplary active agents include, but are not limited to, therapeutic agents, diagnostic agents (e.g.. contrast agents), and any combinations thereof.
  • the active agent present in a silk matrix e.g., a silk microsphere), composition, or the like can include a labile active agent, e.g., an agent that can undergo chemical, physical, or biological change, degradation and/or deactivation after exposure to a specified condition, e.g., high temperatures, high humidity, light exposure, and any combinations thereof.
  • a labile active agent e.g., an agent that can undergo chemical, physical, or biological change, degradation and/or deactivation after exposure to a specified condition, e.g., high temperatures, high humidity, light exposure, and any combinations thereof.
  • the active agent present in the silk matrix can include a temperature-sensitive active agent, e.g., an active agent that will lose at least about 30% or more, of its original activity 7 or bioactivity, upon exposure to a temperature of at least about 10° C. or above, including at least about 15° C. or above, at least about room temperature or above, or at least about body temperature (e.g., about 37° C.) or above.
  • a temperature-sensitive active agent e.g., an active agent that will lose at least about 30% or more, of its original activity 7 or bioactivity, upon exposure to a temperature of at least about 10° C. or above, including at least about 15° C. or above, at least about room temperature or above, or at least about body temperature (e.g., about 37° C.) or above.
  • the active agent can be generally present in the silk matrix (e.g., a silk microsphere), composition, or the like in an amount of about 0.01% (w/w) to about 70% (w/w), or about 0.1% (w/w) to about 50% (w/w), or about 1% (w/w) to about 30% (w/w).
  • the active agent can be present on a surface of the silk matrix (e.g., a silk microsphere), composition, or the like and/or encapsulated and dispersed in the silk matrix (e.g., a silk microsphere), composition, or the like homogeneously or heterogeneously or in a gradient.
  • the active agent can be added into the silk solution, which is then subjected to the methods described herein for preparing a silk matrix (e.g., a silk microsphere), composition, or the like.
  • the active agent can be coated on a surface of the silk matrix (e.g., a silk microsphere), composition, or the like.
  • the active agent can be loaded in a silk matrix (e.g., a silk microsphere), composition, or the like by incubating the silk microsphere in a solution of the active agent for a period of time, during which an amount of the active agent can diffuse into the silk matrix (e.g...
  • the additive is a therapeutic agent.
  • therapeutic agent means a molecule, group of molecules, complex or substance administered to an organism for diagnostic, therapeutic, preventative medical, or veterinary purposes.
  • This term can also be used in reference to agriceutical, workplace, military, industrial and environmental therapeutics or remedies comprising selected molecules or selected nucleic acid sequences capable of recognizing cellular receptors, membrane receptors, hormone receptors, therapeutic receptors, microbes, viruses or selected targets comprising or capable of contacting plants, animals and/or humans.
  • nucleic acids and compounds comprising nucleic acids that produce a therapeutic effect for example deoxyribonucleic acid (DNA), ribonucleic acid (RNA), nucleic acid analogues (e g., locked nucleic acid (LNA), peptide nucleic acid (PNA), xeno nucleic acid (XNA)), or mixtures or combinations thereof, including, for example, DNA nanoplexes, siRNA, microRNA, shRNA, aptamers, ribozymes, decoy nucleic acids, antisense nucleic acids, RNA activators, and the like.
  • any therapeutic agent can be included in the composition provided herein.
  • therapeutic agent also includes an agent that is capable of providing a local or systemic biological, physiological, or therapeutic effect in the biological system to which it is applied.
  • the therapeutic agent can act to control infection or inflammation, enhance cell grow th and tissue regeneration, control tumor growth, act as an analgesic, promote anti-cell attachment, and enhance bone growth, among other functions.
  • suitable therapeutic agents can include anti-viral agents, hormones, antibodies, or therapeutic proteins.
  • Other therapeutic agents include prodrugs, which are agents that are not biologically active when administered but, upon administration to a subject are converted to biologically active agents through metabolism or some other mechanism.
  • a silk-based drug delivery’ composition can contain one therapeutic agent or combinations of two or more therapeutic agents.
  • a therapeutic agent can include a wide variety 7 of different compounds, including chemical compounds and mixtures of chemical compounds, e.g., small organic or inorganic molecules; saccharines; oligosaccharides; polysaccharides; biological macromolecules, e.g., peptides, proteins, and peptide analogs and derivatives; peptidomimetics; antibodies and antigen binding fragments thereof; nucleic acids; nucleic acid analogs and derivatives; an extract made from biological materials such as bacteria, plants, fungi, or animal cells; animal tissues; naturally occurring or synthetic compositions; and any combinations thereof.
  • the therapeutic agent is a small molecule.
  • bioactivity' as used herein in reference to an active agent, generally refers to the ability of an active agent to interact with a biological target and/or to produce an effect on a biological target.
  • bioactivity can include, without limitation, elicitation of a stimulatory, inhibitory, regulatory, toxic or lethal response in a biological target.
  • the biological target can be a molecule or a cell.
  • a bioactivity can refer to the ability' of an active agent to modulate the effect/activity of an enzyme, block a receptor, stimulate a receptor, modulate the expression level of one or more genes, modulate cell proliferation, modulate cell division, modulate cell morphology, or any combination thereof.
  • a bioactivity can refer to the ability of a compound to produce a toxic effect in a cell.
  • exemplary cellular responses include, but are not limited to, lysis, apoptosis, growth inhibition, and growth promotion; production, secretion, and surface expression of a protein or other molecule of interest by the cell; membrane surface molecule activation including receptor activation; transmembrane ion transports; transcriptional regulations: changes in viability of the cell; changes in cell morphology; changes in presence or expression of an intracellular component of the cell; changes in gene expression or transcripts; changes in the activity of an enzyme produced within the cell; and changes in the presence or expression of a ligand and/or receptor (e g., protein expression and/or binding activity ).
  • a ligand and/or receptor e g., protein expression and/or binding activity
  • Bioactivity 7 can be determined in some embodiments, for example, by assaying a cellular response.
  • bioactivity includes, but is not limited to, epitope or antigen binding affinity, the in vivo and/or in vitro stability of the antibody, the immunogenic properties of the antibody, e.g., when administered to a human subject, and/or the ability to neutralize or antagonize the bioactivity of a target molecule in vivo or in vitro.
  • the aforementioned properties or characteristics can be observed or measured using art-recognized techniques including, but not limited to, scintillation proximity assays, ELISA, ORIGEN immunoassay (IGEN), fluorescence quenching, fluorescence ELISA, competitive ELISA, SPR analysis including, but not limited to, SPR analysis using a BIAcore biosensor, in vitro and in vivo neutralization assays (see, for example. International Publication No. WO 2006/062685), receptor binding, and immunohistochemistry with tissue sections from different sources including human, primate, or any other source as needed.
  • the “bioactivity” includes immunogenicity, the definition of which is discussed in detail later.
  • the “bioactivity” includes infectivity, the definition of which is discussed in detail later.
  • the “bioactivity” refers to the ability of a contrast agent when administered to a subject to enhance the contrast of structures or fluids within the subject's body.
  • the bioactivity of a contrast agent also includes, but is not limited to, its ability to interact with a biological environment and/or influence the response of another molecule under certain conditions.
  • small molecule can refer to compounds that are “natural productlike,” however, the term “small molecule” is not limited to “natural product-like” compounds. Rather, a small molecule is typically characterized in that it contains several carbon — carbon bonds, and has a molecular weight of less than 5000 Daltons (5 kDa), preferably less than 3 kDa, still more preferably less than 2 kDa, and most preferably less than 1 kDa. In some cases it is preferred that a small molecule have a molecular weight equal to or less than 700 Daltons.
  • Exemplary therapeutic agents include, but are not limited to, those found in Harrison’s Principles of Internal Medicine, 13th Edition, Eds. T.R. Harrison et al. McGraw-Hill N.Y.. NY; Physicians’ Desk Reference. 50th Edition, 1997, Oradell New Jersey, Medical Economics Co.; Pharmacological Basis of Therapeutics, 8th Edition, Goodman and Gilman, 1990; United States Pharmacopeia, The National Formulary, ETSP XII NF XVII, 1990, the complete contents of all of which are incorporated herein by reference.
  • Therapeutic agents include the herein disclosed categories and specific examples. It is not intended that the category be limited by the specific examples. Those of ordinary skill in the art will recognize also numerous other compounds that fall within the categories and that are useful according to the present disclosure. Examples include a radiosensitizer, a steroid, a xanthine, a beta- 2-agonist bronchodilator, an anti-inflammatory agent, an analgesic agent, a calcium antagonist, an angiotensin-converting enzyme inhibitors, a beta-blocker, a centrally active alpha- agonist, an alpha- 1 -antagonist, an anticholinergic/antispasmodic agent, a vasopressin analogue, an anti arrhythmic agent, an antiparkinsonian agent, an antiangina/antihypertensive agent, an anticoagulant agent, an antiplatelet agent, a sedative, an ansiolytic agent, a peptidic agent, a biopolymeric agent, an antineoplastic agent,
  • the pharmaceutically active agent can be coumarin, albumin, steroids such as betamethasone, dexamethasone, methylprednisolone, prednisolone, prednisone, triamcinolone, budesonide, hydrocortisone, and pharmaceutically acceptable hydrocortisone derivatives; xanthines such as theophylline and doxophylline; beta-2 - agonist bronchodilators such as salbutamol, fenterol, clenbuterol, bambuterol, salmeterol, fenoterol; antiinflammatory agents, including antiasthmatic anti-inflammatory agents, antiarthritis antiinflammatory agents, and non-steroidal antiinflammatory agents, examples of which include but are not limited to sulfides, mesalamine, budesonide, salazopyrin, diclofenac, pharmaceutically acceptable diclofenac salts, nimesulide, naproxene, acetaminophen,
  • steroids such as
  • antiangina agents and antihypertensive agents such as isosorbide mononitrate, isosorbide dinitrate, propranolol, atenolol and verapamil
  • anticoagulant and antiplatelet agents such as Coumadin, warfarin, acetylsalicylic acid, and ticlopidine
  • sedatives such as benzodiazapines and barbiturates
  • ansiolytic agents such as lorazepam, bromazepam, and diazepam
  • peptidic and biopolymeric agents such as calcitonin, leuprolide and other LHRH agonists, hirudin, cyclosporin, insulin, somatostatin, protirelin, interferon, desmopressin, somatotropin, thymopentin, pidotimod, erythropoietin, interleukins, mel
  • laxatives such as senna concentrate, casanthranol, bisacodyl, and sodium picosulphate
  • antidiarrheal agents such as difenoxine hydrochloride, loperamide hydrochloride, furazolidone, diphenoxylate hdyrochloride, and microorganisms
  • vaccines such as bacterial and viral vaccines
  • antimicrobial agents such as penicillins, cephalosporins, and macrolides
  • antifungal agents such as imidazolic and triazolic derivatives: and nucleic acids such as DNA sequences encoding for biological proteins, and antisense oligonucleotides.
  • Anti-cancer agents include alkylating agents, platinum agents, antimetabolites, topoisomerase inhibitors, antitumor antibiotics, antimitotic agents, aromatase inhibitors, thymidylate synthase inhibitors, DNA antagonists, famesyltransferase inhibitors, pump inhibitors, histone acetyltransferase inhibitors, metalloproteinase inhibitors, ribonucleoside reductase inhibitors, TNF alpha agonists/antagonists, endothelinA receptor antagonists, retinoic acid receptor agonists, immunomodulators, hormonal and antihormonal agents, photodynamic agents, and ty rosine kinase inhibitors.
  • Antibiotics include aminoglycosides (e.g.. gentamicin, tobramycin, netilmicin, streptomycin, amikacin, neomycin), bacitracin, corbapenems (e.g., imipenem/cislastatin), cephalosporins, colistin, methenamine, monobactams (e.g., aztreonam), penicillins (e.g., penicillin G, penicillinV, methicillin, natcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, piperacillin, mezlocillin, azlocillin), polymyxin B, quinolones, and vancomycin; and bacteriostatic agents such as chloramphenicol, clindanyan, macrolides (e.g., erythromycin, azithromycin, clarithro), macrol
  • Enzyme inhibitors are substances which inhibit an enzymatic reaction.
  • enzyme inhibitors include edrophonium chloride, N-methylphysostigmine, neostigmine bromide, physostigmine sulfate, tacrine, tacrine, 1 -hydroxy maleate, iodotubercidin, p- bromotetramiisole, 10- (alpha-diethylaminopropionyl)-phenothiazine hydrochloride, calmidazolium chloride, hemicholinium-3,3,5-dinitrocatechol, diacylglycerol kinase inhibitor I, diacylglycerol kinase inhibitor II, 3 -phenylpropargylamine, N°-monomethyl-Larginine acetate, carbidopa.
  • 2-cyclooctyl-2 -hydroxy ethylamine hydrochloride 2.3- dichloro-a-methylbenzylamine (DCMB), 8,9-dichloro-2,3,4, 5 -tetrahydro- lH-2-benzazepine hydrochloride, p-amino glutethimide, p-aminoglutethimide tartrate.
  • Antihistamines include pyrilamine, chlorpheniramine, and tetrahydrazoline, among others.
  • Anti-inflammatory agents include corticosteroids, nonsteroidal anti-inflammatory drugs (e g., aspirin, phenylbutazone, indomethacin, sulindac, tolmetin, ibuprofen, piroxicam, and fenamates), acetaminophen, phenacetin, gold salts, chloroquine.
  • Muscle relaxants include mephenesin, methocarbomal, cyclobenzaprine hydrochloride, trihexylphenidyl hydrochloride, levodopa/carbidopa, and biperiden.
  • Anti-spasmodics include atropine, scopolamine, oxyphenonium, and papaverine.
  • Analgesics include aspirin, phenybutazone, idomethacin, sulindac, tolmetic, ibuprofen, piroxicam, fenamates, acetaminophen, phenacetin, morphine sulfate, codeine sulfate, meperidine, nalorphine, opioids (e.g., codeine sulfate, fentanyl citrate, hydrocodone bitartrate, loperamide, morphine sulfate, noscapine, norcodeine, normorphine, thebaine, nor- binaltorphimine, buprenorphine, chlomaltrexamine, funaltrexamione, nalbuphine, nalorphine, naloxone, naloxonazine, naltrexone, and naltrindole), procaine, lidocain, tetracaine and dibucaine
  • Ophthalmic agents include sodium fluorescein, rose bengal, methacholine, adrenaline, cocaine, atropine, alpha-chymotrypsin, hyaluronidase, betaxalol, pilocarpine, timolol, timolol salts, and combinations thereof.
  • Prostaglandins are art recognized and are a class of naturally occurring chemically related long-chain hydroxy fatty acids that have a variety of biological effects.
  • Anti-depressants are substances capable of preventing or relieving depression.
  • anti-depressants include imipramine, amitriptyline, nortripty line, protripty line, desipramine, amoxapine, doxepin. maprotiline, tranylcypromine, phenelzine, and isocarboxazide.
  • Trophic factors are factors whose continued presence improves the viability or longevity of a cell trophic factors include, without limitation, platelet-derived growth factor (PDGP), neutrophilactivating protein, monocy te chemoattractant protein, macrophage- inflammatory' protein, platelet factor, platelet basic protein, and melanoma growth stimulating activity; epidermal growth factor, transforming growth factor (alpha), fibroblast growth factor, platelet- derived endothelial cell growth factor, insulin-like growth factor, glial derived growth neurotrophic factor, ciliary neurotrophic factor, nen e grow th factor, bone grow th/cartilage- inducing factor (alpha and beta), bone morphogenetic proteins, interleukins (e.g., interleukin inhibitors or interleukin receptors, including interleukin 1 through interleukin 10), interferons (e.g., interferon alpha, beta and gamma), hematopoietic PDGP
  • Hormones include estrogens (e.g., estradiol, estrone, estriol, diethylstibestrol, quinestrol, chlorotrianisene, ethinyl estradiol, mestranol), anti-estrogens (e.g., clomiphene, tamoxifen), progestins (e.g., medroxyprogesterone, norethindrone, hydroxy progesterone, norgestrel), antiprogestin (mifepristone), androgens (e.g, testosterone cypionate, fluoxymesterone, danazol, testolactone), anti-androgens (e.g., cyproterone acetate, flutamide).
  • estrogens e.g., estradiol, estrone, estriol, diethylstibestrol, quinestrol, chlorotrianisene, ethinyl estradiol, mestran
  • thyroid hormones e.g., triiodothyronne, thyroxine, propylthiouracil, methimazole, and iodixode
  • pituitary hormones e.g., corticotropin, sumutotropin, oxytocin, and vasopressin.
  • Hormones are commonly employed in hormone replacement therapy and / or for purposes of birth control.
  • Steroid hormones, such as prednisone are also used as immunosuppressants and anti-inflammatories.
  • the additive is an agent that stimulates tissue formation, and/or healing and regrowth of natural tissues, and any combinations thereof.
  • Agents that increase formation of new tissues and/or stimulates healing or regrowth of native tissue at the site of injection can include, but are not limited to, fibroblast growth factor (FGF), transforming growth factor-beta (TGF-beta, platelet-derived growth factor (PDGF), epidermal growth factors (EGFs), connective tissue activated peptides (CTAPs), osteogenic factors including bone morphogenic proteins, heparin, angiotensin II (A-II) and fragments thereof, insulin-like growth factors, tumor necrosis factors, interleukins, colony stimulating factors, erythropoietin, nerve growth factors, interferons, biologically active analogs, fragments, and derivatives of such growth factors, and any combinations thereof.
  • FGF fibroblast growth factor
  • TGF-beta transforming growth factor-beta
  • PDGF platelet-derived growth factor
  • EGFs epidermal growth factors
  • CTAPs connective tissue activated peptides
  • osteogenic factors
  • the silk composition can further comprise at least one additional material for soft tissue augmentation, e.g., dermal filler materials, including, but not limited to, poly(methyl methacrylate) microspheres, hydroxylapatite, poly(L-lactic acid), collagen, elastin, and glycosaminoglycans, hyaluronic acid, commercial dermal filler products such as BOTOX® (from Allergan), DYSPORT®, COSMODERM®, EVOLENCE®, RADIESSE®,RESTYLANE®, JUVEDERM® (from Allergan), SCULPTRA®, PERLANE®, and CAPTIQEIE®, and any combinations thereof.
  • dermal filler materials including, but not limited to, poly(methyl methacrylate) microspheres, hydroxylapatite, poly(L-lactic acid), collagen, elastin, and glycosaminoglycans, hyaluronic acid, commercial dermal filler products such as BOTOX® (from
  • the additive is a wound healing agent.
  • a wound healing agent is a compound or composition that actively promotes wound healing process.
  • Exemplary w ound healing agents include, but are not limited to dexpanthenol; growth factors; enzymes, hormones; povidon-iodide; Patty acids; anti -infl ammatory agents; antibiotics; antimicrobials; antiseptics; cytokines; thrombin; angalgesics; opioids; aminoxyls; furoxans; nitrosothiols: nitrates and anthocyanins; nucleosides, such as adenosine; and nucleotides, such as adenosine diphosphate (ADP) and adenosine triphosphate (ATP); neutotransmitter/neuromodulators.
  • ADP adenosine diphosphate
  • ATP adenosine triphosphate
  • the active agents provided herein are immunogens.
  • the immunogen is a vaccine. Most vaccines are sensitive to environmental conditions under which they are stored and/or transported.
  • freezing may increase reactogenicity (e.g., capability of causing an immunological reaction) and/or loss of potency for some vaccines (e.g., HepB, and DTaP/IPV/FQB), or cause hairline cracks in the container, leading to contamination.
  • some vaccines e.g., BCG, Varicella, and MMR
  • Many vaccines e.g., BCG, MMR, Varicella, Meningococcal C Conjugate, and most DTaP-containing vaccines
  • compositions and methods provided herein also provide for stabilization of vaccines regardless of the cold chain and/or other environmental conditions.
  • the additive is a cell, e.g., a biological cell.
  • Cells useful for incorporation into the composition can come from any source, e.g., mammalian, insect, plant, etc.
  • the cell can be a human, rat or mouse cell.
  • cells to be used with the compositions provided herein can be any types of cells.
  • the cells should be viable when encapsulated within compositions.
  • cells that can be used with the composition include, but are not limited to, mammalian cells (e.g.
  • exemplary cells that can be can be used with the compositions include platelets, activated platelets, stem cells, totipotent cells, pluripotent cells, and/or embryonic stem cells.
  • exemplary cells that can be encapsulated within compositions include, but are not limited to, primary cells and/or cell lines from any tissue.
  • cardiomyocytes myocytes, hepatocytes, keratinocytes, melanocytes, neurons, astrocytes, embryonic stem cells, adult stem cells, hematopoietic stem cells, hematopoietic cells (e.g. monocytes, neutrophils, macrophages, etc.), ameloblasts, fibroblasts, chondrocytes, osteoblasts, osteoclasts, neurons, sperm cells, egg cells, liver cells, epithelial cells from lung, epithelial cells from gut, epithelial cells from intestine, liver, epithelial cells from skin, etc., and/or hybrids thereof, can be included in the silk/platelet compositions disclosed herein.
  • Cells listed herein represent an exemplary, not comprehensive, list of cells.
  • Cells can be obtained from donors (allogenic) or from recipients (autologous). Cells can be obtained, as a non-limiting example, by biopsy or other surgical means known to those skilled in the art.
  • the cell can be a genetically modified cell.
  • a cell can be genetically modified to express and secrete a desired compound, e.g. a bioactive agent, a growth factor, differentiation factor, cytokines, and the like.
  • a desired compound e.g. a bioactive agent, a growth factor, differentiation factor, cytokines, and the like.
  • Differentiated cells that have been reprogrammed into stem cells can also be used.
  • human skin cells reprogrammed into embryonic stem cells by the transduction of Oct3/4, Sox2, c-Myc and Klf4 (Junying Yu, et. ah, Science, 2007, 318, 1917-1920 and Takahashi K. et. ah. Cell, 2007. 131 . 1-12).
  • the terms “include” and “including” have the same meaning as the terms “comprise” and “comprising.”
  • the terms “comprise” and “comprising” should be interpreted as being “open” transitional terms that permit the inclusion of additional components further to those components recited in the claims.
  • the terms “consist” and “consisting of’ should be interpreted as being “closed” transitional terms that do not permit the inclusion of additional components other than the components recited in the claims.
  • the term “consisting essentially of’ should be interpreted to be partially closed and allowing the inclusion only of additional components that do not fundamentally alter the nature of the claimed subject matter.
  • Example 1 concerns the fabrication of holographic silk coatings that can be applied on food in solid state, such as chips. Holographic thin films are obtained by casting silk fibroin solution on a diffraction grating and peeling it off the substrate once dry- (Fig. 1).
  • Silk fibroin films with diffraction grating were fabricated by casting a low concentration silk solution on a PDMS template of a diffraction grating. Upon solution drying, a diffractive, thin-film can be peeled off from the grating. The free-standing silk grating was then applied on a solid chip. The grating retained its optical properties upon application on the chip, which then displayed holographic properties.
  • the holographic transfer may be tailored to the surface roughness of the food item being coated. For example, for wavy chips, a successful transfer method involved preparing slices of the holographic film and applying each one on the chip. Smoother food items might not require this additional step.
  • the use of a powder made of holographic microparticles might be beneficial to have a colorful coating visible from a broad range of angles.
  • the holographic film can be applied on the solid surface of the food, or dispersed into beverages, upon suitable treatment of the silk film to make it hydrophobic.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Sont divulgués des films comestibles à image holographique transférable. Des produits alimentaires comprenant ces films peuvent comporter une image holographique sur une surface sur laquelle est appliqué le film. Les films comportent un motif d'image holographique sur une première surface de film et une partie de substrat sans motif. La cristallinité de feuillets bêta est réglée pour maintenir le motif d'image holographique lors de l'exposition à diverses conditions entraînant généralement une perte d'image alimentaire. Les films comportent de fines caractéristiques physiques qui génèrent l'image holographique tout en assurant une excellente fidélité d'image lors de l'utilisation.
PCT/US2024/045544 2023-09-06 2024-09-06 Films comestibles à image holographique transférable et procédés associés Pending WO2025054426A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363580896P 2023-09-06 2023-09-06
US63/580,896 2023-09-06

Publications (1)

Publication Number Publication Date
WO2025054426A1 true WO2025054426A1 (fr) 2025-03-13

Family

ID=94924279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/045544 Pending WO2025054426A1 (fr) 2023-09-06 2024-09-06 Films comestibles à image holographique transférable et procédés associés

Country Status (1)

Country Link
WO (1) WO2025054426A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110135697A1 (en) * 2008-06-18 2011-06-09 Trustees Of Tufts College Edible holographic silk products
US20150104390A1 (en) * 2009-07-20 2015-04-16 Tufts University / Trustees Of Tufts College All-protein implantable, resorbable reflectors
US20150202304A1 (en) * 2012-07-13 2015-07-23 Tufts University Encapsulation of immiscible phases in silk fibroin biomaterials

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110135697A1 (en) * 2008-06-18 2011-06-09 Trustees Of Tufts College Edible holographic silk products
US20150104390A1 (en) * 2009-07-20 2015-04-16 Tufts University / Trustees Of Tufts College All-protein implantable, resorbable reflectors
US20150202304A1 (en) * 2012-07-13 2015-07-23 Tufts University Encapsulation of immiscible phases in silk fibroin biomaterials

Similar Documents

Publication Publication Date Title
US20240082405A1 (en) Low Molecular Weight Silk Compositions and Stabilizing Silk Compositions
US10731046B2 (en) Biopolymer-based inks and use thereof
Pritchard et al. Silk fibroin encapsulated powder reservoirs for sustained release of adenosine
US11376329B2 (en) Low molecular weight silk compositions and stabilizing silk compositions
EP2872114A1 (fr) Encapsulation de fragrance et/ou d'arômes dans des biomatières de fibroïne
JP2012533780A (ja) タンパク質のみからなる移植可能な吸収性反射体
US20210155812A1 (en) Silk ink compositions and methods of making and using the same
Gherasim et al. Bioactive ibuprofen-loaded PLGA coatings for multifunctional surface modification of medical devices
WO2025054426A1 (fr) Films comestibles à image holographique transférable et procédés associés
Taurina et al. The gel formulation of the aqueous phase of snakehead fish (Channa striata) extract with various combinations of HPMC K4M and Carbopol 934
Song et al. Inflammatory response study of gellan gum impregnated duck’s feet derived collagen sponges
WO2024158919A2 (fr) Bioplastiques en soie et leur procédé de production
Kuo et al. Inverted colloidal crystal scaffolds for uniform cartilage regeneration
Kiryukhin et al. Arrays of Biocompatible and Mechanically Robust Microchambers Made of Protein–Polyphenol–Clay Multilayer Films
WO2025144993A1 (fr) Capteurs à micro-aiguilles de soie optique transdermique pour surveillance continue d'analytes physiologiques dans un fluide interstitiel
WO2025193717A1 (fr) Assemblage de biopolymères provoqué par le son
WO2025091012A1 (fr) Cuir de soie amélioré et ses procédés de fabrication et d'utilisation
WO2025259797A2 (fr) Mousse de soie composite et matériaux fibreux, leurs procédés de production et d'utilisation
WO2024259420A2 (fr) Systèmes et procédés de bioimpression à sec avec des biopolymères
WO2024145272A1 (fr) Support osseux modulaire
US20250325495A1 (en) Silk nanoparticle synthesis: tuning size, dispersity, and surface chemistry for drug delivery
WO2025259801A2 (fr) Fabrication additive (fa) par dépôt pour crèmes fouettées à base de soie
WO2025231379A1 (fr) Adhésifs de coacervat à l'état solide et leurs procédés de fabrication et d'utilisation
WO2025179185A1 (fr) Cuir de soie résistant à l'eau et matériaux associés
WO2025227091A1 (fr) Crèmes de soie fouettées améliorées et leurs procédés de fabrication et d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24863659

Country of ref document: EP

Kind code of ref document: A1